[Form 4] Cidara Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cidara Therapeutics insider sale to cover RSU taxes Nicole Davarpanah, the company's Chief Medical Officer, sold 474 shares of Cidara Therapeutics common stock on 09/11/2025 to satisfy tax withholding obligations tied to vested restricted stock units. The weighted-average sale price reported is $62.8627, with transaction prices ranging from $62.86 to $63.50. After the reported sale, the reporting person beneficially owns 31,418 shares; this total includes 200 shares purchased through the company Employee Stock Purchase Plan on May 20, 2025. The Form 4 was executed by an attorney-in-fact on 09/15/2025.

Positive

• Full disclosure of a sell-to-cover transaction and price range, showing compliance with reporting rules
• Substantial retained ownership: reporting person still beneficially owns 31,418 shares after the transaction

Negative

• Insider sold shares (474) — although described as sell-to-cover, sales can be viewed negatively by some investors
• Limited detail on exact share-level executions within the price range; reporting person offers to provide details on request

Insights

Financial Analyst

TL;DR: Routine sell-to-cover for RSU tax withholding; small transaction relative to total holdings, limited market impact.

The Form 4 shows a disposition of 474 shares via a sell-to-cover tied to RSU settlement rather than an open-market discretionary sale. The weighted-average price is $62.8627, with a narrow reported price range, suggesting routine execution. The reporting person retains 31,418 shares post-transaction, which indicates continued significant ownership. From a financial perspective, this filing is a standard insider tax-withholding action and unlikely to materially affect CDTX's valuation.

Corporate Governance Expert

TL;DR: Proper disclosure of an RSU-related sell-to-cover; demonstrates compliance with Section 16 reporting obligations.

The filing clearly states the sale was to cover tax withholding for vested RSUs and includes an explanation of the weighted-average price range and inclusion of ESPP shares. The signature by an attorney-in-fact is present and the form identifies the reporting person as an officer (Chief Medical Officer). This is a routine, compliant disclosure without indications of unusual timing or governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Davarpanah Nicole Negar

(Last) (First) (Middle)

6310 NANCY RIDGE DRIVE

SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		S(1)		474	D	$62.8627(2)	31,418(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.86 to $63.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. Includes 200 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2025.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nicole Davarpanah report on the Form 4 for CDTX?

The Form 4 reports a sale of 474 shares on 09/11/2025 to cover tax withholding for vested RSUs; weighted-average price $62.8627.

Why were the shares sold according to the filing?

The filing states the sale was a sell-to-cover transaction to satisfy tax withholding obligations related to RSU vesting, not a discretionary sale.

How many CDTX shares does the reporting person own after the transaction?

After the reported transaction the reporting person beneficially owns 31,418 shares, which includes 200 ESPP shares purchased on May 20, 2025.

What was the price range for the sold shares?

The shares were sold in multiple transactions at prices ranging from $62.86 to $63.50; the weighted-average price reported is $62.8627.

Who signed the Form 4 and when?

The Form 4 was signed by an attorney-in-fact, /s/ Shane Ward, on 09/15/2025.